Recent months have seen much press given to incompetence in the clinics. In spite of massive investments in biomedical research over the past few decades, some basic tenets of good healthcare, such as elementary hygiene, remain our downfall. The average citizen of industrialized nations expects treatments for most illnesses and assumes the right to nearly perfect judgment in their physicians. However, for both mainstream procedures and treatments through clinical trial, old hazards still abound that have raised renewed concerns.
The research community was rocked in late 1999 with the death of Jesse Gelsinger in a gene therapy trial at the University of Pennsylvania. Hearings were held and investigations conducted to determine what went wrong with the study: was accepted practice followed, were the institutional review boards (IRBs) (responsible for overseeing clinical research protocols) structured properly, and did federal regulations need revamping? Conflicts between healthcare, academic and private interests and a lack of appropriate regulation all contributed to the tragedy. Then last fall, Ellen Roche, a laboratory technician at Johns Hopkins Medical School, died of complications due to her participation in a clinical study of asthma. This unleashed a whole new round of inspections and a search for better procedures to prevent such incidents. With so many immunotherapies on the horizon, safety concerns and procedural problems with the conduct of clinical trials need rapid resolution with improved reporting, so potential benefits to the public are not hampered by an inability to gather the appropriate safety and efficacy data. Trial participants must be safeguarded, and the design of trials needs a basis of solid science, rather than wishful extrapolation from limited animal studies. Many trials do not fall under government jurisdiction, as they are conducted by private companies or are not part of the drug approval process, which may put participants at additional risk.
Transplantation usually brings to mind questions of histocompatibility, rejection and immunosuppression. But these questions are moot if more fundamental concerns are not dealt with-such as the provision of sanitary organs and tissues. Technical advances have increased the demand for replacement tissues and organs and helped to fuel the increase in the use of cadaver tissues. But the collection, extraction and sanitizing of such tissues is not rigorously policed, nor are procedures standardized. As of March 2002, the Centers for Disease Control and Prevention had found 26 patients in the US that had been infected with bacteria from their tissue grafts, with one patient dying from standard knee surgery after receiving a contaminated cadaver cartilage graft. In other cases, transplant recipients have come down with Chagas disease because donors' organs had latent infections of Trypanosoma cruzi. Many transplantations, of course, use tissue from live donors, which negates concerns of clostridium spore contamination. But recently, even the donors themselves have been hit with life-threatening complications after donating liver sections to relatives. It isn't clear how many transplant donors suffer adverse reactions, as there are no clear requirements to report to a central registry.
Thus, as was the case with the initial gene therapy trials, minimal reporting of adverse effects and inadequate oversight leads to an inability to track potential anomalies before they become dangerous problems. The experimental protocols through which the deaths of Roche and Gelsinger occurred raised questions as to the thoroughness of the IRBs of US hospitals and academic medical facilities. Could their deaths have been prevented? IRBs at most institutions are underresourced and overburdened. These boards are made up of investigators whose time is split between getting their research published, tending to their patients and attaining tenure. Insufficient compensation for the efforts of those who serve on the boards plague the system. Although many institutions have been reviewing the structure of their IRB processes, the ultimate goal of protecting the subjects, rather than being in compliance with regulations, needs reinforcement.
Biomedical research continues to identify new targets that are ripe for intervention. These new insights lead to animal studies and ultimately to more clinical trial protocols. Medical schools in the US have already seen an increase in submissions to IRBs, without a commensurate increase in the IRB workforce. Until IRB participation is as important to tenure decisions as is publication in top-tier journals, it is irresponsible to continue to push even greater numbers of protocols through the process. Scientific innovation, financial motives and patient need are converging in a dangerously combustible mixture that is driving the system to its limits. Ensuring basic sanitary conditions for all procedures, while reviewing the safety of the newest experimental procedures, are two sides of same coin. Both require appropriate federal oversight and reporting requirements. Even in the current atmosphere of healthcare cost-containment, biomedical investigators must continue to support IRBs and to emphasize the importance of strengthening the translational systems. of their medical schools. Bringing the fruits of publicly supported biomedical research to its patrons and improving public health depends on it.
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